Kobre & Kim and Baker & Partners Announce Partnership with Bentham IMF to Investigate Alleged Overcharging by Patent Renewal Services Company CPA Global
International law firm Kobre & Kim, along with leading Jersey law firm Baker & Partners, announced today that they have entered into a funding arrangement with Bentham IMF to investigate and possibly sue CPA Global, alleging systematic and widespread overcharging of clients for patent renewal services. The firms are also working with the patent renewals consulting business Patent Annuity Costs Limited, headed by Peter Rouse.
CPA Global is one of the world’s largest patent renewal companies, reportedly processing more than 2 million patent renewals per year.
The potential actions will allege that CPA Global breached standard service contracts with what may be tens of thousands of clients through concealed mark-ups, in at least one case estimated to exceed 90 percent.
The proposed legal proceedings would be commenced in Jersey, one of the UK’s Channel Islands, where CPA Global is incorporated, on behalf of CPA Global clients whose agreements select Jersey as the forum for any disputes. Bentham IMF will provide non-recourse funding to CPA Global customers who wish to pursue claims against CPA Global.
James Corbett QC of Kobre & Kim, who is leading the investigation and proposed action, said the following:
"Based on the investigation so far, the overcharging could be shocking. Based on models, the aggregate over-charges could total hundreds of millions of dollars over a ten-year claim period."
Baker & Partners’ Senior Partner Stephen Baker said:
"We engaged with Bentham IMF to help clients enforce their rights on a risk-free basis without the need to secure representation. Given the international nature of CPA Global’s business, we have partnered with a global firm to work with our experienced Jersey team to seek effective redress for claimants from around the world."
Bentham IMF Investment Manager Matthew Harrison said:
"Patent holders worldwide contract with CPA Global for the renewal of rights associated with their most valued assets. CPA Global appears to have breached those contracts. Bentham IMF’s funding will enable Kobre & Kim and Baker & Partners to rectify CPA Global’s treatment of its customers while sparing the patent holders from incurring any fees and costs to participate in the litigation."
The potential litigation is funded by Bentham IMF. Participants will not be required to pay any fees unless their claim is successfully resolved, and then only from sums awarded by the Court.
CPA Global customers, past and present, can register for the potential action without charge or obligation at www.cpaglobal-litigation.com. To find out more about the investigation, please contact email@example.com or call global toll free number +1 833 204 1724.
About Bentham IMF
Bentham IMF is the U.S. arm of publicly listed IMF Bentham Limited (ASX: IMF), one of the most successful litigation funding companies in the world, with a portfolio that has a total claim size value of $3.8 billion AUD. Together, Bentham has 11 offices throughout the U.S., Australia, Canada and Asia and provides funding to clients in jurisdictions including the U.S., Australia, Canada, New Zealand, Hong Kong and Singapore. Bentham has reviewed thousands of commercial cases in the past 16 years, funding to completion more than 162 cases and generating $2.1 billion AUD in recoveries. It has achieved a 91% success rate, with clients utilizing Bentham funding retaining an average of 62% of all case proceeds. Information about Bentham can be found at https://www.benthamimf.com/.
About Kobre & Kim
Kobre & Kim is an Am Law 200 law firm focused exclusively on disputes and investigations, particularly international matters involving fraud or misconduct. Our Intellectual Property & Technology Litigation Group focuses on large-scale, cross-border litigation common in IP-related class actions. The team understands complex technology and has represented the world’s foremost research and academic institutions, as well as industry leaders with strong brands and market relationships. We recognize the importance of preserving our clients’ reputations when they engage in litigation, and we work from the outset to maintain their credibility both within and outside the legal proceedings. Our cross-disciplinary team is qualified in multiple jurisdictions across the U.S., Asia, EMEA and the Caribbean, and our global reach allows us to effectively advocate for clients around the world. Information about Kobre & Kim can be found at https://kobrekim.com/.
About Baker & Partners
Baker & Partners is a specialist litigation and dispute resolution practice based in Jersey. The firm has been at the forefront of some of the most complex and high value litigation in the Island. The firm specialises in fraud; asset tracing and recovery; civil and commercial litigation; trusts disputes; regulation and insolvency. The firm's clients include governments, high-net-worth individuals, professional services firms and local and international financial institutions. Baker & Partners’ lawyers have extensive practical experience in the courts of not only Jersey but also England and Wales. Their skills, both inside and outside of the courtroom, enable the firm to achieve clients’ aims in an efficient and cost-effective way. Further information can be located on the Baker & Partners website at http://www.bakerandpartners.com.
About Patent Annuity Costs Limited
Patent Annuity Costs Limited was created to address the specific needs of users of patent annuity payment providers arising from what is a stubbornly opaque market sector that patent holders are ill-equipped to address. The company has joined with procurement experts Positive Purchasing Limited to offer ‘Patent Plus’, a service that equips patent holders to identify opportunities for cost reduction and better manage their supplier relationships. Information about Patent Annuity Costs Limited can be found at http://www.pacipr.com/.
Kobre & Kim:
Stefanie Trilling, +1 646 448 6213
Baker & Partners:
Louise McNamee, +44 1534 766254
Patent Annuity Costs Limited:
Peter Rouse, +44 7737 128174
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Versum Materials Celebrates the Grand Opening of Its Research and Development Facility in Hometown, PA19.4.2018 23:37 | Tiedote
Versum Materials, Inc. (NYSE: VSM), a leading materials supplier to the semiconductor industry, announced today the grand opening of its new research and development (R&D) facility at its semiconductor materials manufacturing site in Hometown, Pennsylvania. The ribbon-cutting ceremony took place April 10, 2018. Versum employees, members of the community, local government, customers and strategic partners attended the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419006305/en/ Versum Materials ribbon-cutting ceremony at the company's new R&D facility in Hometown, PA. (Photo: Business Wire) The state-of-the-art R&D laboratory is dedicated to new materials used in the manufacture of semiconductors. Scientists in the facility will synthesize and purify new molecules down to parts per billion impurity levels and below using the latest technologies available in the industry. The researchers can assess the applications f
Pharnext to Showcase PLEOTHERAPY™ R&D Platform at the 8th Annual Global Orphan Drug Conference19.4.2018 18:45 | Tiedote
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced that Rodolphe Hajj, Ph.D., the Company’s Chief Pharmacology Officer, will present at the 8th Annual Global Orphan Drug Conference. The presentation will take place as follows: Date & Time: Wednesday April 25th at 4:40 pm EST Title: “Next generation drug repurposing using network pharmacology to develop new therapeutic entities for rare diseases” Venue: Gaylord National Harbor Hotel, Oxon Hill, MD, U.S. Pharnext’s team will also attend the 2018 American Academy of Neurology Annual Meeting as a first-time exhibitor (booth 908). The meeting will take place on April 21-27, 2018 in Los Angeles, CA, U.S. If you are interested in meeting the Pharnext management team during these events, please send an email to firstname.lastname@example.org. About Pharnext Pharne
New Study Investigates the Utility of Masimo SpHb® in Post-operative Red Blood Cell (RBC) Transfusion Best Practices19.4.2018 18:01 | Tiedote
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Annual Meeting of the Network for the Advancement of Patient Blood Management, Haemostatis and Thrombosis (NATA), in which researchers investigated the utility of Masimo noninvasive and continuous hemoglobin (SpHb®) in supporting and enhancing red blood cell (RBC) transfusion best practices as part of post-operative patient blood management (PBM).1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180419005949/en/ Masimo Radical-7® with SpHb® and RD rainbow SET™ Sensor (Photo: Business Wire) In the study, Prof. Baricchi and colleagues in the Transfusion Medicine Unit, AUSL-IRCCS of Reggio Emilia and at the Department of Medicine and Surgery at the University of Parma, Italy, sought to evaluate the appropriateness of post-operative RBC transfusion over a three-year period (2013-2015), before and after implementation of a patient blood managem
Synteract Repositions Itself with Centers of Therapeutic Development and Unveils Updated Brand Platform19.4.2018 17:06 | Tiedote
Synteract, an innovative contract research organization (CRO) providing full-service, Phase I-IV services to biopharma companies bringing new medicines to market, has enhanced its focus. The CRO today announced the creation of therapeutic centers of development that include some of the most progressive in the biopharma industry: oncology, especially leading edge immunotherapy studies, neuro-degenerative disorders, pediatrics, and rare and orphan disease. In addition, Synteract revealed its new market positioning with an updated logo, tagline, and website to reinforce its core capabilities. Synteract’s leadership has been proven in these core development areas, over its nearly 30-year history, through its contributions to more than 240 product approvals. Formal establishment of its new centers of development bring more visibility to Synteract’s longstanding, specialized expertise in these complex areas of clinical research. Synteract CEO Steve Powell says, “By aligning operational excel
Nel ASA: Receives Additional Purchase Order from Nikola19.4.2018 17:00 | Tiedote
Nel ASA (Nel, OSE: NEL) has received a USD 5.5 million purchase order from Nikola Motor Company (Nikola), as part of the previously announced hydrogen stations. “We are very proud to announce that we have received an additional order from Nikola related to the electrolyzer and fueling solution for their prototype trucks. The order marks a strengthening of our partnership and is a recognition of the level of competence our team and hydrogen solutions can offer. We look forward to supplying the demo stations, which will lay the groundwork for the world’s largest, most efficient network of low-cost hydrogen production and fueling sites,” says Jon André Løkke, Chief Executive Officer of Nel. On November 15, 2017, Nikola and Nel announced the exclusive partnership and a purchase order for two so-called demo hydrogen refueling stations for Nikola's fleet of prototype hydrogen trucks. The partnership aims at developing low-cost, renewable hydrogen production and fueling sites for the potentia
Voith and Franka Emika Form a Strategic Partnership19.4.2018 16:39 | Tiedote
The technology company Voith and the Munich-based robotics company Franka Emika have entered into a strategic partnership. Part of the strategic partnership is the establishment of a new joint venture called Voith Robotics – A Voith and Franka Emika Company. The company, with headquarters in Munich, is to become a global system supplier for robot-assisted automation in the digital age. Voith Robotics will offer self-teaching lightweight robots made by Franka Emika, along with software solutions, apps, services and process consulting, to customers in various industries and markets throughout the world. As part of the strategic partnership Voith will also have a direct stake in Franka Emika, thus emphasizing the long-term and strategic commitment by the two companies to cooperation. Martin Scherrer, formerly a member of the Board of Management of Voith Paper, will be the new chief executive officer of Voith Robotics, which is to be managed by Voith. The still very young market for collab
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme